EMA panel recommends approval of Eli Lilly’s Foundayo weight‑loss pill
On 16 Oct 2026 the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion on Foundayo (orforglipron) for obesity and type‑2 diabetes. The recommendation moves the drug toward final marketing authorisation by the European Commission. Lilly reported $98 million of Foundayo sales in Q2 and insiders have sold $2.66 billion of its shares over the past year.
Why it matters
The EMA endorsement is a critical step for Lilly to enter the EU market, which analysts estimate could be worth over $100 billion by 2030. Bernstein analyst Courtney Breen expects an EU rollout by year‑end, implying near‑term revenue upside.
Key facts
- 1The EMA CHMP recommended marketing authorization for Foundayo on 16 Oct 2026. ksl.com
- 2Foundayo generated $98 million in second‑quarter revenue. finance.biggo.com
- 3Insiders have sold $2.66 billion of Lilly shares in the past 12 months. gurufocus.com
- 4Lilly’s stock traded at $1,251.61, about 20.7% below its GF Value of $1,578.54. gurufocus.com
- 5Lilly shares rose 1.8% after the EMA recommendation, heading for the best weekly gain in nearly four months. finance.yahoo.com
Summary written by AlphAI AI Desk from 10 of 10 sources. Not investment advice. Figures are as stated by the linked sources.